Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSNeo-DC in Malignant Solid Tumors
NCT07752953Recruiting
- Start
- May 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of personalized neoantigen-pulsed autologous dendritic cell injections in malignant solid tumor. Primary endpoint: Objective Response Rate at 12 months. Started May 2026; status: recruiting.
02
Drugs
personalized neoantigen-pulsed autologous dendritic cell injections
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07752953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752953.